Seeking Alpha

Leerink steps to sidelines on Amicus amid lack of near-term catalysts

  • Leerink cuts Amicus Therapeutics (FOLD -2.5%) to Market Perform from Outperform.
  • Analyst Joseph Schwartz sees "relatively limited news flow over the near-term" and thinks the company's "aim of offering an enzyme replacement therapy that is optimized with a coformulated pharmacologic chaperone for every lysosomal storage disorder [is] compelling but may take some time."
  • Price target is $3.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: